After conducting checks at the NACF conference, RBC Capital expects Vertex to report solid Q3 results. The firm expects the company's launch of its Orkambi treatment to be positive, and it thinks the company will become "very profitable." RBC is also upbeat on the prospects for a "triple pill" that it says the company will launch next year. The firm recommends buying the stock ahead of the company's Q3 results on October 28 and it keeps a $145 price target and Outperform rating on the shares.

Vertex Pharmaceuticals and TreeFrog Therapeutics announced that Vertex has obtained an exclusive license to TreeFrog's proprietary cell manufacturing technology, C-Stem, to optimize production of Vertex's cell therapies for type 1 diabetes, or T1D. TreeFrog and Vertex will collaborate to scale-up TreeFrog's process to produce and amplify cells for Vertex's T1D therapies. TreeFrog's proprietary technology platform, C-Stem, is designed to mimic the natural microenvironment, allowing cells to grow exponentially in 3D. The technology will enhance Vertex's ability to generate large amounts of fully differentiated cells for its portfolio of T1D cell therapies.